Medical Xpress reports a small pilot study where people coming off GLP-1 treatment got structured support, with early signs it may help them keep weight off.
Recap by typeshit. Full story at Medical Xpress.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
As more people get weight loss drugs through telehealth, the pharmacies making compounded versions are drawing scrutiny. TIME looks at what buyers should know.
Pothier says social media and telehealth pulled GLP-1s partly out of doctors' hands, pushing Novo and Lilly to rethink launches. Novo CEO Mike Doustdar weighs in too.
Loading…